Reprint

Sex Hormone Receptor Signals in Human Malignancies

Edited by
September 2019
150 pages
  • ISBN978-3-03921-173-9 (Paperback)
  • ISBN978-3-03921-174-6 (PDF)

This book is a reprint of the Special Issue Sex Hormone Receptor Signals in Human Malignancies that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary
Sex steroids, including androgens, estrogens, and progestogens, are knownto have widespread physiological actions beyond the reproductive systemvia binding to the sex hormone receptors. Meanwhile, emerging evidence hasindicated that sex hormone receptor signals are involved in the outgrowth ofsome malignancies, such as prostate and breast carcinomas, as well as othersthat have not traditionally been considered as endocrine-related neoplasms. ThisSpecial Issue “Sex Hormone Receptor Signals in Human Malignancies” coversvarious aspects of the potential role of sex hormone receptors and related signalsin prostate cancer, breast cancer, and other neoplastic conditions by depictingpromising findings derived from in vitro and in vivo experiments as well as theanalyses of surgical specimens. The current observations described may thusprovide a unique insight into novel or known functions of sex hormone receptorsand related molecules.
Format
  • Paperback
License
© 2019 by the authors; CC BY-NC-ND license
Keywords
sex hormone receptors; salivary gland tumors; therapeutic targets; ELK1; immunohistochemistry; upper urinary tract urothelial carcinoma; prognosis; androgen receptor; castration-resistant prostate cancer; heterogeneous nuclear ribonucleoprotein K; androgen receptor; androgen deprivation therapy; COBRA1; NELFB; androgen receptor; CRPC; ethinylestradiol; levonorgestrel; keratinocytes; fibroblasts; melanocytes; melanoma; ultraviolet radiation; breast cancer; FOXA1; drug screening and proteomics; estrogen receptor alpha; nuclear factor erythroid 2-related factor 2; ovarian cancer; immunohistochemistry; breast cancer; epidermal growth factor receptor; estrogen; estrogen receptor; G-protein coupled estrogen receptor; breast cancer; progesterone receptor negative; mutational profiling; PI3K pathway; TP53; n/a